Serum cystatin C correlates negatively with viral load in treatment-naïve children with chronic hepatitis C

Journal of Pediatric Gastroenterology and Nutrition

Volumn 54, Issue 3, 2012, Pages 364-368

  Behairy, Behairy E ^a   Saber, Magdy A ^a   Elhenawy, Ibrahim A ^a   Abou Zeinah, Sahar S ^a   El Sharawy, Ahmed A ^b   Sira, Mostafa M ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

^b MENOUFIA UNIVERSITY   (Egypt)

Author keywords

cystatin C; cysteine protease; genotype 4; hepatitis C virus; viral load

Indexed keywords

CYSTATIN C;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER FUNCTION; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; VIREMIA; VIRUS LOAD;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CYSTATIN C; CYSTEINE PROTEASES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; MALE; REFERENCE VALUES; TRANSAMINASES; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 84857790025     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31823e98c2     Document Type: Article

References (36)

1. Welbourn S, Pause A. The hepatitis C virus NS2/3 protease. Curr Issues Mol Biol 2007;9:63-9.
2. El-Raziky MS, El-Hawary M, Esmat G, et al. Prevalence and risk factors of asymptomatic hepatitis C virus infection in Egyptian children. World J Gastroenterol 2007;13:1828-32. (Pubitemid 46706017)
3. Liew M, Erali M, Page S, et al. Hepatitis C genotyping by denaturing high-performance liquid chromatography. J Clin Microbiol 2004; 42:158-63. (Pubitemid 38082714)
4. Webster DP, Klenerman P, Collier J, et al. Development of novel treatments for hepatitis C. Lancet Infect Dis 2009;9:108-17.
5. Glenn JS. Molecular virology of the hepatitis C virus: implication for novel therapies. Clin Liver Dis 2005;9:353-69. (Pubitemid 40968200)
6. Kolykhalov AA, Mihalik K, Feinstone SM, et al. Hepatitis C virusencoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J Virol 2000;74:2046-51. (Pubitemid 30434065)
7. Lorenz IC, Marcotrigiano J, Dentzer TG, et al. Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. Nature 2006;442:831-5. (Pubitemid 44258915)
8. She Y, Liao Q, Chen X, et al. Hepatitis C virus (HCV) NS2 protein upregulates HCV IRES-dependent translation and down-regulates NS5B RdRp activity. Arch Virol 2008;153:1991-7.
9. Liu Q, Bhat RA, Prince AM, et al. The hepatitis C virus NS2 protein generated by NS2-3 autocleavage is required for NS5A phosphorylation. Biochem Biophys Res Commun 1999;254:572-7. (Pubitemid 29290507)
10. Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007;20:23-38. (Pubitemid 46167766)
11. Beran RK, Pyle AM. Hepatitis C viral NS3-4A protease activity is enhanced by the NS3 helicase. J Biol Chem 2008;283:29929-37.
12. Korolenko TA, Filatova TG, Cherkanova MS, et al. Cystatins: cysteine proteases regulation and disturbances in tumors and inflammation. Biomed Khim 2008;54:210-7. (Pubitemid 351798270)
13. Jiborn T, Abrahamson M,Wallin H, et al. Cystatin C is highly expressed in the human male reproductive system. J Androl 2004;25:564-72. (Pubitemid 38880191)
14. Mukherjee S, Ukil A, Das PK. Immunomodulatory peptide from cystatin, a natural cysteine protease inhibitor, against leishmaniasis as a model macrophage disease. Antimicrob Agents Chemother 2007; 51:1700-7. (Pubitemid 46744148)
15. Takeuchi T, Isobe S, Sato K, et al. Cystatin C: a possible sensitive marker for detecting potential kidney injury after computed tomography coronary angiography. J Comput Assist Tomogr 2011;35:240-5.
16. Roos JF, Doust J, Tett SE, et al. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children-a meta-analysis. Clin Biochem 2007;40:383-91.
17. Satoh-Asahara N, Suganami T, Majima T, et al. Urinary cystatin C as a potential risk marker for cardiovascular disease and chronic kidney disease in patients with obesity and metabolic syndrome. Clin J Am Soc Nephrol 2011;6:265-73.
18. Lassus J, Harjola VP. Cystatin C: a step forward in assessing kidney function and cardiovascular risk. Heart Fail Rev 2011.
19. Uemura O, Ushijima K, Nagai T, et al. Measurements of serum cystatin C concentrations underestimate renal dysfunction in pediatric patients with chronic kidney disease. Clin Exp Nephrol 2011;15:535-8.
20. Royakkers AA, Korevaar JC, van Suijlen JD, et al. Serum and urine cystatin C are poor biomarkers for acute kidney injury and renal replacement therapy. Intensive Care Med 2011;37:493-501.
21. Takeuchi M, Fukuda Y, Nakano I, et al. Elevation of serum cystatin C concentrations in patients with chronic liver disease. Eur J Gastroenterol Hepatol 2001;13:951-5. (Pubitemid 32757014)
22. Chu SC, Wang CP, Chang YH, et al. Increased cystatin C serum concentrations in patients with hepatic diseases of various severities. Clin Chim Acta 2004;341:133-8.
23. Lebensztejn DM, Skiba E, Kaczmarski M, et al. Serum cystatin C concentration does not predict advanced liver disease in children with chronic hepatitis B. Clin Chim Acta 2004;347:227-8. (Pubitemid 39099627)
24. Alisi A, Comparcola D, Nobili V. Treatment of chronic hepatitis C in children: is it necessary and, if so, in whom? J Hepatol 2010;52:472-4.
25. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52.
26. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
27. Esmat G, Metwally M, Zalata KR, et al. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol 2007;46:620-7. (Pubitemid 46402951)
28. Bjorck L, Grubb A, Kjellen L. Cystatin C, a human proteinase inhibitor, blocks replication of herpes simplex virus. J Virol 1990;64:941-3. (Pubitemid 20032717)
29. Collins AR, Grubb A. Inhibitory effects of recombinant human cystatin C on human coronaviruses. Antimicrob Agents Chemother 1991;35:2444-6.
30. Peri P, Hukkanen V, Nuutila KS, et al. The cysteine protease inhibitors cystatins inhibit herpes simplex virus type 1-induced apoptosis and virus yield in HEp-2 cells. J Gen Virol 2007;88:2101-5. (Pubitemid 47194203)
31. Vray B, Hartmann S, Hoebeke J. Immunomodulatory properties of cystatins. Cell Mol Life Sci 2002;59:1503-12. (Pubitemid 35239306)
32. Castillo I, Rodriguez-Inigo E, Lopez-Alcorocho JM, et al. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis 2006;43:1277-83. (Pubitemid 44706453)
33. Castillo I, Rodriguez-Inigo E, Bartolome J, et al. Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. Gut 2005;54:682-5. (Pubitemid 40559255)
34. Ekstrom U, Wallin H, Lorenzo J, et al. Internalization of cystatin C in human cell lines. FEBS J 2008;275:4571-82.
35. Frendeus KH, Wallin H, Janciauskiene S, et al. Macrophage responses to interferon-gamma are dependent on cystatin C levels. Int J Biochem Cell Biol 2009;41:2262-9.
36. El-Araby HA, Sira MM, Behairy EB, et al. Interferon induction regimen for chronic hepatitis C genotype 4 in Egyptian children. J Pediatr Infect Dis 2010;5:233-41.